ITCMDBv1
Clinical TrialID 2546

A Phase II Trial of Phenoxodiol in Patients With Castrate and Non-Castrate Prostate Cancer

NCT00557037

Prostate Cancer

Back to Browse

Relationship Network

Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.

Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...

Record Fields

Scalar fields from the final clinical_trial record.

Clinical Trial Id
2546
Evidence Id
2546
Core Evidence Id
2546
Source Clinical Trial Id
2526
Herb2 Clinical Trial Id
HBCT002526
Nct Id
NCT00557037
Title
A Phase II Trial of Phenoxodiol in Patients With Castrate and Non-Castrate Prostate Cancer
Status
Completed
Phase
Phase 2
Study Result
No
Study Condition
Prostate Cancer
Study Type
Interventional
Study Design
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
Intervention
DRUG: Phenoxodiol
Intervention Allocation
Intervention Model
Single_Group
Intervention Mask
Intervention Purpose
Treatment
Gender
Male
Age
Adult, Older_Adult
Enrollment
60
Outcome Measure
The proportion of patients that have a 50% post-therapy PSA decline at 12 weeks in patients with: a)Chemotherapy naïve androgen independent disease (Group A) b)Rising PSA after radical prostatectomy or radiotherapy that are androgen dependent (Group B), 12 weeks
Sponsor Collaborator
MEI Pharma, Inc.
Funded By
INDUSTRY
Location
Yale Cancer Center, New Haven, Connecticut, 06520, United States|VA Connecticut Healthcare System, West Haven, Connecticut, 06516, United States
Other Id
Yale 0703002467
Start Date
2007-11
Primary Completion Date
Completion Date
2009-11
First Posted
2007-11-12
Results First Posted
Last Update Posted
2010-04-08
Study Document
Study Url
https://clinicaltrials.gov/study/NCT00557037
Title Cn
Title En
A Phase II Trial of Phenoxodiol in Patients With Castrate and Non-Castrate Prostate Cancer
Bilingual Status
semi_complete